POCUSars-CoV-2: Accuracy of Lung Ultrasound in the Diagnosis of covid19 Pneumonia

Sponsor
Ospedale di Latisana (Other)
Overall Status
Unknown status
CT.gov ID
NCT04370275
Collaborator
(none)
235
1
1.2
188.2

Study Details

Study Description

Brief Summary

Is Lung Ultrasound really useful in diagnosing COVID19? What can be the usefulness of the Lung Ultrasound in the COVID19 epidemic? In the current state of the art, Sensitivity, Specificity, Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of Lung Ultrasound in the diagnosis of COVID-19 are not yet known.

Alveolar-interstitial lung diseases such as viral pneumonia and ARDS seems to have a specific ultrasound pattern that distinguishes them from bacterial pneumonia, preferentially represented by B lines, morphological irregularity of the pleural line, and small subpleural consolidations, but they could share these patterns with other pathologies, reducing specificity.

In Italy, the Lung Ultrasound represents a consolidated method for the evaluation and management of all patients who come to the ER, and what we are sure of is its high sensitivity in identifying pathological patterns.

Our preliminary data suggest that Lung Ultrasound is highly reliable not to include but to exclude the diagnosis of COVID-19 in patients with respiratory symptoms.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    One of the first scientific papers published on the COVID-19 epidemic in China showed that patients still asymptomatic or paucisymptomatic, positive for SARS-CoV-2 on the RT-PCR test, presented chest CT images referring to parenchymal infiltrate with a prevalent appearance at ground-glass compatible with initial COVID-19 pneumonia.

    An ongoing study anticipates that the sensitivity of chest CT is higher than that of the RT-PCR molecular test for SARS-CoV-2 (performed on the pharyngeal swab or sputum) (50 out of 51, 98%, 95% CI: 90% -100% vs 36 out of 51, 71%, IC95%: 56% -83%) in the early diagnosis of COVID-19.

    Recent work seems to shows that Lung Ultrasound is effective in the clinical evaluation and diagnosis of COVID-19 pneumonia.

    In a previous study, in addition, sensitivity and specificity of the Lung Ultrasound in the early diagnosis of H1N1 flu pneumonia was 94.1% (32 out of 34) and 84.8% respectively (28 out of 33), with a positive predictive value of 86.5% (32 out of 37) and a negative predictive value of 93.3% (28 out of 30).

    The concordance between the lung ultrasound findings and the lung lesions found on CT has recently been demonstrated ("lobe-specific" concordance equal to 87%; "lung-specific concordance" equal to 92.5 % for the right lung and 83.6% for the left lung).

    These data suggest to better explore the diagnostic accuracy of the Lung Ultrasound in SARS-CoV-2 infection.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    235 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Accuracy of Lung Ultrasound in the Diagnosis of covid19 Pneumonia: a Multicenter Study in the Italian Outbreak
    Actual Study Start Date :
    Apr 23, 2020
    Anticipated Primary Completion Date :
    May 23, 2020
    Anticipated Study Completion Date :
    May 31, 2020

    Outcome Measures

    Primary Outcome Measures

    1. Negative Predictive Value of Lung Ultrasound in the diagnosis of COVID-19 [30 days]

      Lung Ultrasound accuracy in rule-out of patients with respiratory symptoms (fever and / or cough and / or dyspnoea) during the SARS-CoV-2 epidemic compared to nasopharyngeal swab and a composite reference standards

    Secondary Outcome Measures

    1. Positive Predictive Value of Lung Ultrasound in the diagnosis of COVID-19 [30 days]

      Lung Ultrasound accuracy in rule-in of patients with respiratory symptoms (fever and / or cough and / or dyspnoea) during the SARS-CoV-2 epidemic compared to nasopharyngeal swab and a composite reference standards

    2. Sensitivity and Specificity of Lung Ultrasound in the diagnosis of COVID-19 [30 days]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Fever and/or

    • Cough and/or

    • Dyspnoea

    Exclusion Criteria:
    • No one

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 SC Pronto Soccorso e Medicina d'Urgenza Latisana Udine Italy 33053

    Sponsors and Collaborators

    • Ospedale di Latisana

    Investigators

    • Principal Investigator: Roberto Copetti, MD, Director, Ospedale di Latisana

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Ospedale di Latisana
    ClinicalTrials.gov Identifier:
    NCT04370275
    Other Study ID Numbers:
    • CEUR-2020-Os-086
    First Posted:
    Apr 30, 2020
    Last Update Posted:
    Apr 30, 2020
    Last Verified:
    Apr 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Ospedale di Latisana
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 30, 2020